MRVI

+ Watchlist + Portfolio

Maravai LifeSciences Holdings, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.22
52-Week Range: $2.28 – $8.38
Market Cap: $3.07B
P/E (TTM): —
EPS (TTM): -0.53
Dividend Yield: —

Advanced Metrics

Price/Book: 5.78
PEG Ratio: —
Return on Equity: -33.05%
Return on Assets: -5.71%
Gross Margin: 35.71%
Operating Margin: -29.40%
Profit Margin: -37.07%
Current Ratio: 4.05
Debt/Equity: 0.61
Total Debt: $218.10M
Free Cash Flow: $-3.62M
Revenue Growth: 8.50%
Earnings Growth: —
Enterprise Value: $1.37B

MRVI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$883.00M	$288.94M	$259.19M	$185.74M
Cost of Revenue	$168.96M	$148.74M	$150.88M	$151.75M
Gross Profit	$714.04M	$140.20M	$108.31M	$33.99M
Research & Development	$18.37M	$17.28M	$19.22M	$17.40M
Selling, General & Admin	$129.26M	$151.39M	$161.77M	$145.12M
Operating Expenses	$147.63M	$168.67M	$180.99M	$162.52M
Operating Income	$566.42M	-$28.47M	-$72.68M	-$128.53M
EBITDA	$609.99M	$712.41M	-$156.92M	-$147.51M
Pretax Income	$551.47M	$617.74M	-$261.48M	-$234.97M
Income Tax	$60.81M	$756.11M	-$1.86M	-$4.21M
Net Income	$220.21M	-$119.03M	-$144.85M	-$130.77M
Diluted EPS	1.67	-0.90	-1.05	-0.90
Diluted Shares	255.32M	131.92M	137.91M	144.36M

MRVI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$632.14M	$574.96M	$322.40M	$216.89M
Receivables	$146.81M	$54.60M	$38.52M	$25.50M
Inventory	$43.15M	$51.40M	$50.08M	$40.49M
Current Assets	$847.90M	$699.91M	$429.15M	$296.25M
Total Assets	$2.28B	$1.49B	$1.01B	$770.58M
Current Liabilities	$110.14M	$87.47M	$56.97M	$44.92M
Long-Term Debt	$522.00M	$518.71M	$290.49M	$286.33M
Total Debt	$585.26M	$610.97M	$376.69M	$364.71M
Total Liabilities	$1.38B	$697.57M	$431.04M	$397.87M
Retained Earnings	$404.77M	$285.74M	$140.89M	$10.12M
Shareholders' Equity	$545.22M	$416.75M	$325.29M	$212.38M
Working Capital	$737.76M	$612.44M	$372.18M	$251.33M
Net Debt	—	—	—	$74.88M

MRVI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$535.98M	$126.22M	$7.46M	-$57.57M
Capital Expenditure	-$17.09M	-$65.55M	-$29.66M	-$13.15M
Free Cash Flow	$518.89M	$60.67M	-$22.19M	-$70.72M
Depreciation & Amortisation	$38.10M	$48.78M	$56.87M	$60.47M
Stock-Based Compensation	$18.67M	$34.59M	$49.41M	$30.17M
Investing Cash Flow	-$267.61M	-$122.31M	-$24.32M	-$31.41M
Financing Cash Flow	-$187.50M	-$61.09M	-$235.71M	-$16.50M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	$80.87M	-$57.18M	-$252.56M	-$105.48M

MRVI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$46.85M	$47.40M	$41.63M	$49.87M	$65.84M
Cost of Revenue	$39.13M	$39.63M	$35.98M	$37.02M	$32.14M
Gross Profit	$7.72M	$7.77M	$5.66M	$12.84M	$33.70M
Research & Development	$4.89M	$4.88M	$3.84M	$3.79M	$3.89M
Selling, General & Admin	$39.56M	$38.58M	$35.40M	$31.58M	$29.09M
Operating Expenses	$44.45M	$43.46M	$39.24M	$35.37M	$32.98M
Operating Income	-$36.73M	-$35.69M	-$33.59M	-$22.53M	$720.00K
EBITDA	-$31.00M	-$51.92M	-$22.86M	-$41.72M	$12.20M
Pretax Income	-$52.69M	-$74.13M	-$45.15M	-$63.01M	-$6.53M
Income Tax	$162.00K	-$4.29M	-$92.00K	$6.00K	-$151.00K
Net Income	-$29.95M	-$39.59M	-$25.56M	-$35.68M	-$3.73M
Diluted EPS	-0.21	-0.27	-0.18	-0.24	-0.02
Diluted Shares	143.43M	144.24M	144.68M	145.07M	146.43M

MRVI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$285.05M	$269.91M	$243.57M	$216.89M	$165.92M
Receivables	$28.49M	$27.88M	$22.54M	$25.50M	$33.41M
Inventory	$49.77M	$46.67M	$45.33M	$40.49M	$40.46M
Current Assets	$376.28M	$359.76M	$325.87M	$296.25M	$251.74M
Total Assets	$959.75M	$896.97M	$849.19M	$770.58M	$713.22M
Current Liabilities	$63.16M	$69.68M	$61.57M	$44.92M	$42.62M
Long-Term Debt	$289.50M	$288.44M	$287.38M	$286.33M	$235.57M
Total Debt	$370.62M	$363.59M	$367.94M	$364.71M	$270.88M
Total Liabilities	$429.48M	$428.98M	$417.33M	$397.87M	$344.13M
Retained Earnings	$110.95M	$71.36M	$45.80M	$10.12M	$6.38M
Shareholders' Equity	$300.61M	$265.86M	$245.44M	$212.38M	$211.56M
Working Capital	$313.12M	$290.08M	$264.29M	$251.33M	$209.11M
Net Debt	$9.89M	$23.97M	$49.25M	$74.88M	$75.09M

MRVI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$9.39M	-$10.27M	-$15.15M	-$22.77M	$8.66M
Capital Expenditure	-$4.50M	-$3.61M	-$2.93M	-$2.11M	-$4.44M
Free Cash Flow	-$13.89M	-$13.87M	-$18.08M	-$24.88M	$4.23M
Depreciation & Amortisation	$14.91M	$15.39M	$15.44M	$14.73M	$12.98M
Stock-Based Compensation	$10.40M	$6.79M	$9.06M	$3.93M	$6.74M
Investing Cash Flow	-$23.13M	-$3.24M	-$2.93M	-$2.11M	-$4.44M
Financing Cash Flow	-$4.90M	-$1.53M	-$8.25M	-$1.82M	-$55.23M
Net Change in Cash	-$37.42M	-$15.04M	-$26.32M	-$26.70M	-$51.00M

Market Snapshot

About

Life sciences company producing nucleic acid products critical for mRNA therapeutics, vaccines, and gene therapy development. Supplies lipids, nucleotides, polymerases, and other essential materials to biopharmaceutical researchers and manufacturers.